Archive for October, 2019

Multidomain intervention for Alzheimer’s disease (AD) risk reduction is an emerging therapeutic paradigm. Read & Research Alzheimer’s More

Be the first to comment

The levels and distribution of amyloid deposits in the brain does not correlate well with Alzheimer’s disease (AD) progression. Therefore, it is likely that amyloid precursor protein and its proteolytic fragments other than amyloid β (Aβ) contribute to the onset of AD. Read & Research Alzheimer’s More

Be the first to comment

Odor identification deficits characterize Alzheimer’s disease and other dementias. We examined if intact performance on brief cognitive and odor identification tests predicts lack of transition to dementia. Read & Research Alzheimer’s More

Be the first to comment

This study aimed to determine if later birth year influences trajectory of age-related cognitive decline across racial/ethnic groups and to test whether years of school, childhood socioeconomic status, and cardiovascular disease burden explain such secular trends. Read & Research Alzheimer’s More

Be the first to comment

Differential patterns of brain atrophy on structural magnetic resonance imaging (MRI) revealed four reproducible subtypes of Alzheimer’s disease (AD): (1) “typical”, (2) “limbic-predominant”, (3) “hippocampal-sparing”, and (4) “mild atrophy”. We examined the neurobiological characteristics and clinical progression of these atrophy-defined subtypes. Read & Research Alzheimer’s More

Be the first to comment

A new study of 1,628 older people living in Japan found a 52–74% higher chance of developing dementia in those with higher blood levels of trans fats. Read & Research Alzheimer’s More

Be the first to comment

New research in mice sheds light on the mechanism that explains the causal link between a diet high in salt and a marker of Alzheimer’s disease. Read & Research Alzheimer’s More

Be the first to comment

Synaptic damage, axonal neurodegeneration, and neuroinflammation are common features in Alzheimer’s disease (AD), frontotemporal dementia (FTD), and Creutzfeldt-Jakob disease (CJD). Read & Research Alzheimer’s More

Be the first to comment

Alzheimer’s disease (AD) is linked to neuronal calcium dyshomeostasis, which is associated with network hyperexcitability. Decreased expression of the calcium-binding protein calbindin-D28K (CB) might be a susceptibility factor for AD. The subiculum is affected early in AD, for unknown reasons. Read & Research Alzheimer’s More

Be the first to comment

What is apraxia?"> What is apraxia?

Posted October 24, 2019 By

Apraxia is a neurological disorder that affects a person’s ability to perform everyday movements. Learn more about the symptoms, causes, and types in this article. Read & Research Alzheimer’s More

Be the first to comment

Biotech company Biogen have announced that they will file for official approval of a new Alzheimer’s drug, while results in clinical trials were uncertain. Read & Research Alzheimer’s More

Be the first to comment

Frontotemporal lobar degeneration (FTLD) is the most common form of dementia for those under 60 years of age. Increasing numbers of therapeutics targeting FTLD syndromes are being developed. Read & Research Alzheimer’s More

Be the first to comment

Sensor-based assessment of challenging behaviors in dementia may be useful to support caregivers. Here, we investigated accelerometry as tool for identification and prediction of challenging behaviors. Read & Research Alzheimer’s More

Be the first to comment

Understanding the heterogeneous pathology in Alzheimer’s disease and related tauopathies is one of the most urgent and fundamental challenges facing the discovery of novel disease-modifying therapies. Through monitoring ensembles of toxic and nontoxic tau oligomers spontaneously formed in cells, our biosensor technology can identify tool compounds that modulate tau oligomer Read & Research Alzheimer’s More

Be the first to comment

A new study in twins finds that modifiable factors, such as early family life, may be more important than genes in driving heart and brain health outcomes. Read & Research Alzheimer’s More

Be the first to comment

It is important to establish the natural history of familial frontotemporal lobar degeneration (f-FTLD) and provide clinical and biomarker data for planning these studies, particularly in the asymptomatic phase. Read & Research Alzheimer’s More

Be the first to comment

Multiple immunity biomarkers have been suggested as tracers of neuroinflammation in neurodegeneration. This study aimed to verify findings in cerebrospinal fluid (CSF) samples of Alzheimer’s disease (AD) and Parkinson’s disease (PD) subjects from the network of the European, Innovative Medicines Initiative–funded project AETIONOMY. Read & Research Alzheimer’s More

Be the first to comment

New research shows how frontotemporal dementia progresses and enables scientists to accurately predict how the condition will spread. Read & Research Alzheimer’s More

Be the first to comment

A new study finds that testing memory with sex-specific scores could lead to more females and fewer males receiving a mild cognitive impairment diagnosis. Read & Research Alzheimer’s More

Be the first to comment

We investigated the relation between self-reported hearing loss and risk of subjective cognitive function (SCF) decline among women. Read & Research Alzheimer’s More

Be the first to comment

Prospective studies reporting associations between cognitive performance and subsequent incident dementia have been subject to attrition bias. Furthermore, the extent to which established risk factors account for such associations requires further elucidation. Read & Research Alzheimer’s More

Be the first to comment

A new study attributes the link between tau protein clumping and brain damage in Alzheimer’s disease to brain immune cells called microglia. Read & Research Alzheimer’s More

Be the first to comment

Acetylcholine is a neurotransmitter that plays a key role in brain and muscle function. Here, we look at what acetylcholine does and describe medical conditions linked with it, including Alzheimer’s and Parkinson’s, and their treatments. Read & Research Alzheimer’s More

Be the first to comment

To determine if sleep-disordered breathing (SDB), daytime sleepiness, insomnia, and sleep duration predict seven-year neurocognitive decline in US Hispanics/Latinos (N = 5247). Read & Research Alzheimer’s More

Be the first to comment

Although the relationship between APOE and Alzheimer’s disease (AD) is well established in populations of European descent, the effects of APOE and ancestry on AD risk in diverse populations is not well understood. Read & Research Alzheimer’s More

Be the first to comment

New research in mice suggests that dabigatran, a blood thinning drug, may help delay the development of Alzheimer’s by maintaining normal brain blood flow. Read & Research Alzheimer’s More

Be the first to comment

We examined the influence of enrollment factors demonstrated to differ by race on incident mild cognitive impairment and dementia using Alzheimer’s Disease Center data. Read & Research Alzheimer’s More

Be the first to comment

Alzheimer’s disease (AD) is a disabling, common cause of dementia, and agitation is one of the most common and distressing symptoms for patients with AD. Escitalopram for agitation in Alzheimer’s disease (S-CitAD) tests a novel, clinically derived therapeutic approach to treat agitation in patients with AD. Read & Research Alzheimer’s More

Be the first to comment

The objective of this study was to assess the usefulness of the appropriate use criteria (AUC) for amyloid imaging in an unselected cohort. Read & Research Alzheimer’s More

Be the first to comment

The aim of this study was to investigate the registry-based national time trends in incidence and prevalence rates of dementia from 1996 to 2015. Read & Research Alzheimer’s More

Be the first to comment